Skip to main content

Lyell reports new clinical data from trial of large B-cell lymphoma therapy

Submitted by admin on
snippet

Lyell Immunopharma has reported new clinical data from the Phase I/II clinical trial of autologous dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate, LYL314, along with data from those with large B-cell lymphoma (LBCL) in the third or later line (3L+) setting.

Source
Clinical Trials Arena
Headline
https://www.clinicaltrialsarena.com/news/lyell-b-cell-lymphoma/
News Tags
Lyell Immunopharma
clinical trials
CAR-T
LYL314
large B cell lymphoma

IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO

Submitted by admin on
snippet

Cargo Therapeutics, Inc. has filed for an IPO to raise $300 million for the development of its drug candidates for large B cell lymphoma cancer and other B cell malignancies.

Source
Seeking Alpha
Headline
IPO Update: Cargo Therapeutics Readies Plans For $300 Million IPO
News Tags
Cargo Therapeutics
IPOs
large B cell lymphoma

Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial

Submitted by admin on
snippet

ALPHA2 Trial, Evaluating ALLO-501A in Relapsed/Refractory Large B Cell Lymphoma Patients, is Designed to Leverage the Ease and Convenience of a Single Dose of ALLO-501A
Protocol Supported by Clinical and Translational Data from Phase 1 Trial Indicating Deep Responses are Achievable with a Single Dose of ALLO-501A When Used with a Lymphodepletion Regimen That Includes an Optimized Dose of ALLO-647

Source
Global Newswire
Headline
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
News Tags
Allogene
large B cell lymphoma
clinical trials
ALLO-501a
CAR-T
Subscribe to large B cell lymphoma